首页> 美国卫生研究院文献>British Journal of Cancer >Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
【2h】

Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma

机译:酪氨酸激酶抑制可改善基于蒽环类的T细胞淋巴瘤化疗的疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CHOEP treatment induces cell cycle perturbations and cell death in preclinical models of T-cell lymphoma. , Cell lines were exposed to IC CHOEP for 24 h and 48 h. Cell cycle distribution ( ) and FITC–Annexin V/PI staining ( ) were evaluated by flow cytometry. In panel , early apoptotic cells are Annexin V positive/PI negative, late apoptoticecrotic cells are Annexin V positive/PI positive. The data are the mean ± SD of three independent experiments. Asterisks indicate statistically significant differences (*  p p a, differences are referred to the untreated sample. In panel , statistics was calculated on the total number of dead cells
机译:CHOEP治疗可在T细胞淋巴瘤的临床前模型中诱导细胞周期扰动和细胞死亡。 ,将细胞系暴露于IC CHOEP 24 h和48 h。通过流式细胞术评估细胞周期分布()和FITC-Annexin V / PI染色()。在面板中,早期凋亡细胞是膜联蛋白V阳性/ PI阴性,晚期凋亡/坏死细胞是膜联蛋白V阳性/ PI阳性。数据是三个独立实验的平均值±SD。星号表示统计学上的显着差异(* p p a,差异指的是未经处理的样品。在面板中,对死细胞总数进行了统计计算

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号